{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:54:42Z","timestamp":1792122882074,"version":"4.4.0"},"reference-count":60,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy may significantly improve survival for selected patients with peritoneal surface malignancies, but it has always been criticized due to the high incidence of postoperative morbidity and mortality. Methods: Data were collected from nine Italian centers with peritoneal surface malignancies expertise within a collaborative group of the Italian Society of Surgical Oncology. Complications and mortality rates were recorded, and multivariate Cox analysis was used to identify risk factors. Results: The study included 2576 patients. The procedure was mostly performed for ovarian (27.4%) and colon cancer (22.4%). The median peritoneal cancer index was 13. Overall postoperative morbidity and mortality rates were 34% and 1.6%. A total of 232 (9%) patients required surgical reoperation. Multivariate regression logistic analysis identified the type of perfusion (p \u2264 0.0001), body mass index (p \u2264 0.0001), number of resections (p \u2264 0.0001) and colorectal resections (p \u2264 0.0001) as the strongest predictors of complications, whereas the number of resections (p \u2264 0.0001) and age (p = 0.01) were the strongest predictors of mortality. Conclusions: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is a valuable option of treatment for selected patients with peritoneal carcinomatosis providing low postoperative morbidity and mortality rates, if performed in high-volume specialized centers.<\/jats:p>","DOI":"10.3390\/cancers14235824","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T07:01:30Z","timestamp":1669618890000},"page":"5824","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis"],"prefix":"10.3390","volume":"14","author":[{"given":"Fabio","family":"Carboni","sequence":"first","affiliation":[{"name":"Peritoneal Tumors Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Valle","sequence":"additional","affiliation":[{"name":"Peritoneal Tumors Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vaira","sequence":"additional","affiliation":[{"name":"Candiolo Cancer Institute, FPO\u2014IRCCS, 10060 Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sammartino","sequence":"additional","affiliation":[{"name":"Cytoreductive Surgery and HIPEC Unit, Department of Surgery \u201cPietro Valdoni\u201d, Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orietta","family":"Federici","sequence":"additional","affiliation":[{"name":"Peritoneal Tumors Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7676-9658","authenticated-orcid":false,"given":"Manuela","family":"Robella","sequence":"additional","affiliation":[{"name":"Candiolo Cancer Institute, FPO\u2014IRCCS, 10060 Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Framarini","sequence":"additional","affiliation":[{"name":"Surgery and Advanced Oncological Therapy, Morgagni\u2014Pierantoni Hospital, AUSL Romagna, 47121 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Macr\u00ec","sequence":"additional","affiliation":[{"name":"UOC\u2014PSG con OBI Azienda Ospedaliera Universitaria \u201cG. Martino\u201d, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Sassaroli","sequence":"additional","affiliation":[{"name":"Colorectal Surgical Oncology, Abdominal Oncology Department, \u201cFondazione Giovanni Pascale\u201d IRCCS, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero Vincenzo","family":"Lippolis","sequence":"additional","affiliation":[{"name":"General and Peritoneal Surgery, Department of Surgery, Hospital University Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Giorgio","sequence":"additional","affiliation":[{"name":"Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Biacchi","sequence":"additional","affiliation":[{"name":"Cytoreductive Surgery and HIPEC Unit, Department of Surgery \u201cPietro Valdoni\u201d, Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Martin-Roman","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[{"name":"Department of Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Baratti","sequence":"additional","affiliation":[{"name":"Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jso.26371","article-title":"Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience","volume":"123","author":"Nichiforkin","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1245\/s10434-019-07518-1","article-title":"Improved Survival with Experience: A 10-Year Learning Curve in Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery","volume":"27","author":"Leigh","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s00423-021-02354-y","article-title":"Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of non-primary origin","volume":"406","author":"Carboni","year":"2021","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jso.24248","article-title":"What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1.125 procedures","volume":"113","author":"Passot","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mielko, J., Rawicz-Pruszy\u0144ski, K., S\u0119d\u0142ak, K., G\u0119ca, K., Kwietniewska, M., and Polkowski, W.P. (2020). Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Learning Curve Based on Surgical and Oncological Outcomes. Cancers, 23.","DOI":"10.3390\/cancers12092387"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/jso.25642","article-title":"Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases","volume":"120","author":"Kyang","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","article-title":"Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality","volume":"249","author":"Chua","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.soc.2018.02.009","article-title":"Learning curve, training program and monitorization of surgical performance of peritoneal surface malignancies centers","volume":"27","author":"Kusamura","year":"2018","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/SLA.0000000000004326","article-title":"Centralization and Oncologic Training Reduce Postoperative Morbidity and Failure-to-rescue Rates After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Study on a 10-year National French Practice","volume":"272","author":"Noiret","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/SLA.0000000000005101","article-title":"Half of Postoperative Deaths After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Could be Preventable: A French Root Cause Analysis on 5562 Patients","volume":"274","author":"Glehen","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","article-title":"Intraperitoneal chemotherapy for peritoneal surface malignancy: Experience with 1000 patients","volume":"218","author":"Levine","year":"2014","journal-title":"J. Am. Coll. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e186847","DOI":"10.1001\/jamanetworkopen.2018.6847","article-title":"Morbidity and Mortality Rates Following Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy Compared with Other High-Risk Surgical Oncology Procedures","volume":"2","author":"Foster","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jss.2020.05.085","article-title":"Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"255","author":"Kubi","year":"2020","journal-title":"J. Surg. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1245\/s10434-020-09301-z","article-title":"In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany","volume":"28","author":"Nadiradze","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1245\/s10434-018-6992-6","article-title":"Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients","volume":"26","author":"Piso","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjsurg.2019.09.017","article-title":"Trends in the indications for short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"219","author":"Beal","year":"2020","journal-title":"Am. J. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamasurg.2013.3640","article-title":"Surgical outcomes of hyperthermic intraperitoneal chemotherapy: Analysis of the american college of surgeons national surgical quality improvement program","volume":"149","author":"Jafari","year":"2014","journal-title":"JAMA Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jss.2018.09.032","article-title":"Trends in Outcomes after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy","volume":"234","author":"Gani","year":"2019","journal-title":"J. Surg. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1055-3207(03)00048-6","article-title":"Peritonectomy procedures","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.soc.2018.02.005","article-title":"Techniques and Safety Issues for Intraperitoneal Chemotherapy","volume":"27","year":"2018","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_21","unstructured":"National Cancer Institute (2021, December 01). Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available online: https:\/\/www.meddra.org\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10147-019-01609-5","article-title":"High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"25","author":"Tan","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1245\/s10434-018-6823-9","article-title":"Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies","volume":"25","author":"Choudry","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jss.2019.05.046","article-title":"Incidence and Long-term Outcomes of Patients Requiring Early Reoperation After HIPEC","volume":"244","author":"Lee","year":"2019","journal-title":"J. Surg. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101492","DOI":"10.1016\/j.suronc.2020.11.006","article-title":"A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies","volume":"37","author":"Wiseman","year":"2021","journal-title":"Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/02656736.2017.1367846","article-title":"Ninety-day post-operative morbidity and mortality using the National Cancer Institute\u2019s common terminology criteria for adverse events better describe post-operative outcome after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy","volume":"34","author":"Alyami","year":"2018","journal-title":"Int. J. Hypert."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s11605-014-2477-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: Outcomes from a single tertiary institution","volume":"8","author":"Tabrizian","year":"2014","journal-title":"J. Gastrointest. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00423-014-1253-z","article-title":"Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"400","author":"Desantis","year":"2015","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00423-019-01808-8","article-title":"Re-operations for early postoperative complications after CRS and HIPEC: Indication, timing, procedure, and outcome","volume":"404","author":"Blaj","year":"2019","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00423-019-01805-x","article-title":"Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: Analysis of 384 consecutive cases","volume":"404","author":"Narasimhan","year":"2019","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejso.2020.08.016","article-title":"Feasibility of diaphragmatic interventions in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: A 20-year experience","volume":"47","author":"Carboni","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1245\/s10434-019-07957-w","article-title":"Diagnostic Laparoscopy as a Selection Tool for Patients with Colorectal Peritoneal Metastases to Prevent a Non-therapeutic Laparotomy During Cytoreductive Surgery","volume":"27","author":"Hentzen","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s11605-019-04368-w","article-title":"An 18-year experience in diagnostic laparoscopy of peritoneal carcinomatosis: Results from 744 patients","volume":"24","author":"Carboni","year":"2020","journal-title":"J. Gastrointest. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00464-017-5923-0","article-title":"Laparoscopy as a useful selection tool for patients with prior surgery and peritoneal metastases suitable for multimodality treatment strategies","volume":"32","author":"Boerner","year":"2018","journal-title":"Surg. Endosc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12957-020-01837-4","article-title":"Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy-a national population-based study","volume":"6","author":"Dranichnikov","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11605-019-04463-y","article-title":"Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study","volume":"24","author":"Lee","year":"2020","journal-title":"J. Gastrointest. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jss.2018.09.022","article-title":"Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"234","author":"Paredes","year":"2019","journal-title":"J. Surg. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1245\/s10434-017-6108-8","article-title":"Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy","volume":"25","author":"Kelly","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1245\/s10434-016-5109-3","article-title":"Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis","volume":"23","author":"Martin","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1245\/s10434-020-09547-7","article-title":"Predischarge Prediction of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Derivation and Validation of a Risk Prediction Score","volume":"28","author":"Rieser","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/SLA.0b013e31825704e3","article-title":"Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"256","author":"Baratti","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jss.2018.08.018","article-title":"Non-home Discharge and Prolonged Length of Stay After Cytoreductive Surgery and HIPEC","volume":"233","author":"Burguete","year":"2019","journal-title":"J. Surg. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1245\/s10434-013-3223-z","article-title":"Morbidity and mortality of cytoreduction with intraperitoneal chemotherapy: Outcomes from the ACS NSQIP database","volume":"21","author":"Bartlett","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4251\/wjgo.v12.i7.756","article-title":"Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative","volume":"12","author":"Leiting","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Helderman, R.F.C.P.A., L\u00f6ke, D.R., Kok, H.P., Oei, A.L., Tanis, P.J., Franken, N.A.P.K., and Crezee, J. (2019). Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Cancers, 11.","DOI":"10.3390\/cancers11010078"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1245\/s10434-021-10157-0","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of \u2018Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.\u2019","volume":"28","author":"Marano","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1002\/cam4.2204","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: A retrospective cooperative Central-Eastern European study","volume":"8","author":"Yarema","year":"2019","journal-title":"Cancer Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1245\/s10434-017-6111-0","article-title":"Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy","volume":"22","author":"Konstantinidis","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.ejso.2021.04.004","article-title":"Short-term outcomes in older patients with peritoneal malignancy treated with cytoreductive surgery and HIPEC: Experience with 245 patients from a national centre","volume":"47","author":"Keyes","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1245\/s10434-017-6313-5","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Elderly: Is It Reasonable? A Meta-Analysis","volume":"25","author":"Veziant","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2021.05.013","article-title":"Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"162","author":"Chambers","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.surge.2018.01.001","article-title":"Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies","volume":"16","author":"Dreznik","year":"2018","journal-title":"Surgeon"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1245\/s10434-021-10414-2","article-title":"Predicting Early and Late Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"28","author":"Moon","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12094-018-1944-y","article-title":"Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: A prospective observational study","volume":"21","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"235","DOI":"10.21037\/jgo.2018.12.11","article-title":"The effect of intraoperative fluid administration on outcomes of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"10","author":"Shamavonian","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1245\/s10434-018-07092-y","article-title":"Restrictive Intraoperative Fluid Therapy is Associated with Decreased Morbidity and Length of Stay Following Hyperthermic Intraperitoneal Chemoperfusion","volume":"26","author":"Hendrix","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1245\/s10434-019-07644-w","article-title":"Standard Operating Procedures for Anesthesia Management in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improve Patient Outcomes: A Patient Cohort Analysis","volume":"26","author":"Fichmann","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1245\/s10434-020-09501-7","article-title":"Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis","volume":"28","author":"Kubi","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.ejso.2019.07.031","article-title":"Intraoperative packed red blood cell transfusion (iPRBT) and PCI-normalised iPRBT rates (iPRBT\/PCI ratio) negatively affect short- and long-term outcomes of patients undergoing cytoreductive surgery and intraperitoneal chemotherapy\u2014An analysis of 880 patients","volume":"45","author":"Fisher","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1245\/s10434-018-6630-3","article-title":"Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC","volume":"25","author":"Nizri","year":"2018","journal-title":"Ann. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5824\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:27:10Z","timestamp":1760146030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":60,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14235824"],"URL":"https:\/\/doi.org\/10.3390\/cancers14235824","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]}}}